181 related articles for article (PubMed ID: 35031791)
1. Rise of the preprint: how rapid data sharing during COVID-19 has changed science forever.
Watson C
Nat Med; 2022 Jan; 28(1):2-5. PubMed ID: 35031791
[No Abstract] [Full Text] [Related]
2. Flawed ivermectin preprint highlights challenges of COVID drug studies.
Reardon S
Nature; 2021 Aug; 596(7871):173-174. PubMed ID: 34341573
[No Abstract] [Full Text] [Related]
3. Familiar Dermatologic Drugs as Therapies for COVID-19.
Ortega-Peña M; González-Cuevas R
Actas Dermosifiliogr (Engl Ed); 2021 Feb; 112(2):118-126. PubMed ID: 33045209
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection.
Galan LEB; Santos NMD; Asato MS; Araújo JV; de Lima Moreira A; Araújo AMM; Paiva ADP; Portella DGS; Marques FSS; Silva GMA; de Sousa Resende J; Tizolim MR; Santos PL; Buttenbender SF; de Andrade SB; Carbonell RCC; Da Rocha JG; de Souza RGS; da Fonseca AJ
Pathog Glob Health; 2021 Jun; 115(4):235-242. PubMed ID: 33682640
[No Abstract] [Full Text] [Related]
5. How a torrent of COVID science changed research publishing - in seven charts.
Else H
Nature; 2020 Dec; 588(7839):553. PubMed ID: 33328621
[No Abstract] [Full Text] [Related]
6. Possible treatment and strategies for COVID-19: review and assessment.
Trivedi N; Verma A; Kumar D
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12593-12608. PubMed ID: 33336780
[TBL] [Abstract][Full Text] [Related]
7. Ivermectin for preventing and treating COVID-19.
Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
[TBL] [Abstract][Full Text] [Related]
8. Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19.
Kow CS; Hasan SS
Am J Ther; 2021 Aug; 28(5):e616-e619. PubMed ID: 34387564
[No Abstract] [Full Text] [Related]
9. Ivermectin in COVID-19: What do we know?
Pandey S; Pathak SK; Pandey A; Salunke AA; Chawla J; Sharma A; Sharma S; Thivari P; Ratna HVK
Diabetes Metab Syndr; 2020; 14(6):1921-1922. PubMed ID: 33032231
[No Abstract] [Full Text] [Related]
10. The evolving role of preprints in the dissemination of COVID-19 research and their impact on the science communication landscape.
Fraser N; Brierley L; Dey G; Polka JK; Pálfy M; Nanni F; Coates JA
PLoS Biol; 2021 Apr; 19(4):e3000959. PubMed ID: 33798194
[TBL] [Abstract][Full Text] [Related]
11. Pandemic and promise: progress towards finding an effective treatment for Novel Coronavirus 19.
Merone L; Finlay S
Aust N Z J Public Health; 2020 Dec; 44(6):437-439. PubMed ID: 33044799
[No Abstract] [Full Text] [Related]
12. The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.
Lawrence JM; Meyerowitz-Katz G; Heathers JAJ; Brown NJL; Sheldrick KA
Nat Med; 2021 Nov; 27(11):1853-1854. PubMed ID: 34552263
[No Abstract] [Full Text] [Related]
13. Proliferation of Papers and Preprints During the Coronavirus Disease 2019 Pandemic: Progress or Problems With Peer Review?
Vlasschaert C; Topf JM; Hiremath S
Adv Chronic Kidney Dis; 2020 Sep; 27(5):418-426. PubMed ID: 33308508
[TBL] [Abstract][Full Text] [Related]
14. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
[TBL] [Abstract][Full Text] [Related]
15. Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.
Kory P; Meduri GU; Varon J; Iglesias J; Marik PE
Am J Ther; 2021 Apr; 28(3):e299-e318. PubMed ID: 34375047
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19.
Peña-Silva R; Duffull SB; Steer AC; Jaramillo-Rincon SX; Gwee A; Zhu X
Br J Clin Pharmacol; 2021 Mar; 87(3):1589-1590. PubMed ID: 32779815
[No Abstract] [Full Text] [Related]
17. Changes in evidence for studies assessing interventions for COVID-19 reported in preprints: meta-research study.
Oikonomidi T; Boutron I; Pierre O; Cabanac G; Ravaud P;
BMC Med; 2020 Dec; 18(1):402. PubMed ID: 33334338
[TBL] [Abstract][Full Text] [Related]
18. Preprint manuscripts and servers in the era of coronavirus disease 2019.
Nabavi Nouri S; Cohen YA; Madhavan MV; Slomka PJ; Iskandrian AE; Einstein AJ
J Eval Clin Pract; 2021 Feb; 27(1):16-21. PubMed ID: 33094906
[TBL] [Abstract][Full Text] [Related]
19. Ivermectin in dermatology: why it 'mite' be useless against COVID-19.
Roche D; O'Connor C; Murphy M
Clin Exp Dermatol; 2021 Oct; 46(7):1327-1328. PubMed ID: 33896010
[No Abstract] [Full Text] [Related]
20. Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials.
Zein AFMZ; Sulistiyana CS; Raffaelo WM; Pranata R
Diabetes Metab Syndr; 2021; 15(4):102186. PubMed ID: 34237554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
